301267.SHE Huaxia Eye Hospital Group Co. Ltd. A
- Market cap
- CNY 12.6B
- P/E
- 26.8x
- P/B
- 2.24x
- ROE
- 11.1%
- Dividend yield
- 2.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301267.SHE undervalued?
Graham number301267.SHE trades 63.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Huaxia Eye Hospital Group Co. Ltd. A fundamental analysis
No fundamental analysis for Huaxia Eye Hospital Group Co. Ltd. A yet.
Huaxia Eye Hospital Group Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Huaxia Eye Hospital Group Co. Ltd. A
Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis, treatment, and other ophthalmic medical services for patients with eye disease and myopia; prevention and intervention work to the public. It offers services in the areas of cataract, refractive errors, fundus, strabismus and amblyopia, pediatric ophthalmology, ocular surface, glaucoma, orbital and ocular tumors, optometr…
Full company profileHuaxia Eye Hospital Group Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Huaxia Eye Hospital Group Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.51B | 3.06B | 3.23B | 4.01B | 4.03B | 4.14B | 4.46B |
| Gross Profit | 1.06B | 1.41B | 1.55B | 1.97B | 1.78B | 1.79B | 1.99B |
| Operating Income | 495M | 690M | 747M | 912M | 636M | 638M | 861M |
| EBITDA | - | - | 966M | 1.17B | 918M | 954M | 892M |
| Net Income | 334M | 455M | 514M | 666M | 429M | 441M | 622M |
| EPS | 0.45 | 0.61 | 0.61 | 0.79 | 0.51 | 0.52 | 0.74 |
| Balance Sheet | |||||||
| Total Assets | 2.77B | 3.22B | 6.74B | 7.38B | 7.92B | 7.56B | 7.85B |
| Total Liabilities | 1.31B | 1.37B | 1.61B | 1.66B | 1.90B | 2.10B | 2.07B |
| Shareholders' Equity | 1.42B | 1.83B | 5.12B | 5.66B | 5.79B | 5.27B | 5.59B |
| Cash & Short-term Investments | 503M | 953M | 1.35B | 3.92B | 3.49B | 2.52B | 598M |
| Cash Flow | |||||||
| Operating Cash Flow | 591M | 798M | 770M | 961M | 820M | 868M | - |
| Capital Expenditure | 163M | 174M | 235M | 448M | 280M | 232M | 169M |
| Free Cash Flow | 427M | 624M | 535M | 513M | 541M | 636M | 846M |
| Ratios | |||||||
| ROE | 23.6% | 24.8% | 10.0% | 11.8% | 7.4% | 8.4% | 11.1% |
| ROA | 12.1% | 14.1% | 7.6% | 9.0% | 5.4% | 5.8% | 7.9% |
| Net Profit Margin | 13.3% | 14.8% | 15.9% | 16.6% | 10.6% | 10.6% | 14.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Huaxia Eye Hospital Group Co. Ltd. A dividends
- Dividend yield
- 2.07%
- Forward dividend
- 0.26 CNY
- Payout ratio
- 59.2%
- Ex-dividend date
- Jul 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 261M | 0.31 | 59.2% |
| 2024 | CNY 92.1M | 0.11 | 21.5% |
| 2023 | CNY 157M | 0.19 | 23.6% |
| 2022 | CNY 503K | 0.00 | 0.1% |
| 2021 | CNY 158K | 0.00 | 0.0% |
| 2020 | CNY 6.57M | 0.01 | 2.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 11, 2023.
Who owns Huaxia Eye Hospital Group Co. Ltd. A
- Insiders 79.51%
- Institutions 2.83%
- Public & others 17.66%
- Shares outstanding 840M
- Free float 163M
Huaxia Eye Hospital Group Co. Ltd. A company profile
- Company name
- Huaxia Eye Hospital Group Co. Ltd. A
- Ticker
- 301267.SHE
- ISIN
- CNE100005WL5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 8,200
- Fiscal year end
- December
- Address
- No. 999 Wutong West Road, Xiamen, China, 361006
- Phone
- 86 40 0611 2222
- Website
- huaxiaeye.com
About Huaxia Eye Hospital Group Co. Ltd. A
Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis, treatment, and other ophthalmic medical services for patients with eye disease and myopia; prevention and intervention work to the public. It offers services in the areas of cataract, refractive errors, fundus, strabismus and amblyopia, pediatric ophthalmology, ocular surface, glaucoma, orbital and ocular tumors, optometry, and ocular trauma, as well as engages in community services. The company was founded in 1997 and is based in Xiamen, China.
Huaxia Eye Hospital Group Co. Ltd. A management
6- Mr. Qingcan SuChairman of the Board & GM · born 1969
- Ms. Lu Yan ChenFinancial Director & Accounting Supervisor · born 1978
- Mr. Xiaofeng LiDeputy GM & Non-Independent Director · born 1972
- Mr. Nai En CaoBoard Secretary · born 1975
- Mr. Zhiyong ZhangDeputy General Manager · born 1982
- Mr. Bin Bin ZhangDeputy General Manager · born 1964